


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula I



$\text{X} = \text{N}$ or CH ,

$\text{R}^1, \text{R}^3 =$ independently of one another H , OH , OA , CN , Hal , COR^4 or CH_2R^4 ,

$\text{R}^2 =$ an optionally mono- or poly- Hal -substituted, linear or branched alkyl moiety having 1-6 C atoms, or an alkaryl, alkheteroaryl, or heteroaryl moiety,

$\text{R}^4 = \text{OH}$, OA , NH_2 , NHB or NB_2 ,

$\text{A}, \text{B} =$ independently of one another alkyl having 1-6 C atoms,

$m = 2, 3, 4, 5$ or 6 and

$n = 0, 1, 2, 3$ or 4 ,

or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.

2. (Currently Amended) Compounds according to Claim 1 in which

$\text{X} = \text{N}$,

$\text{R}^1, \text{R}^3 =$ independently of one another CN , COR^4 or CH_2R^4 ,

$\text{R}^2 =$ a linear or branched alkyl having 1-6 C atoms, alkaryl, alkheteroaryl, or heteroaryl,

$R^4 = OH, NH_2, NHB$ or NB_2 ,

A, B = independently of one another alkyl having 1-6 C atoms,

m = 4 and

n = 0,


and physiologically acceptable salts, ~~derivatives, solvates and/or~~ stereoisomers thereof, including mixtures thereof in all ratios.

3. (Previously Presented) Compounds according to Claim 1 ~~or~~ 2

- a. 5-[4-[4-(5-cyano-1-methyl-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide
- b. 5-[4-[4-(5-cyano-1-ethyl-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide
- c. 5-[4-[4-(5-cyano-1-isopropyl-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide
- d. 5-[4-[4-(1-benzyl-5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide
- e. 5-[4-[4-(5-cyano-1-propyl-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide
- f. 5-[4-[4-(5-cyano-1-pyridin-2-ylmethyl-1H-indol-3-yl)butyl]piperazin-1-yl]-benzofuran-2-carboxamide
- g. 5-[4-[4-(5-cyano-1-phenethyl-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide

4. (Currently Amended) Process for the preparation of the compounds of the formula I, comprising

- a) reacting a compound of the formula II, in which R^1 and m have the meanings indicated in Claim 1 and Y is a halogen ~~or is an alcohol provided with a protecting group known to the person skilled in the art,~~




with a compound of the formula III, in which R² has the meanings indicated in Claim 1 and Z represents a leaving group




and

b) reacting a compound of the formula IV



obtained in accordance with a) with a compound of the formula V or a salt thereof, in which R³, X and n have the meanings indicated in Claim 1,



in a solvent, optionally with addition of base, at the boiling point of the solvent,
or

- c) converting a base of a compound of the formula I into one of its salts by treatment with an acid.
5. (Canceled)
6. (Currently Amended) Pharmaceutical composition comprising at least one compound according to Claim 1 and/or physiologically acceptable salts,~~solvates~~ or stereoisomers thereof, including mixtures thereof in all ratios, and a pharmaceutically acceptable carrier.
7. (Previously Presented) Pharmaceutical composition, according to Claim 6 comprising further excipients and/or adjuvants.
8. (Currently Amended) Pharmaceutical composition comprising at least one compound according to Claim 1 and/or physiologically acceptable salts,~~solvates~~ or stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
9. (Currently Amended) Process for the preparation of a pharmaceutical composition, comprising bringing a compound according to Claim 1 and/or one of its physiologically acceptable salts,~~solvates~~ or stereoisomers, including mixtures thereof in all ratios, into a suitable dosage form together with a solid, liquid or semi-liquid excipient or adjuvant.
10. (Cancelled)
11. (Cancelled)
12. (Currently Amended) A method of achieving an anxiolytic, antidepressant,

neuroleptic and/or antihypertonic effect and/or for positively influencing obsessive-compulsive disorder (OCD), sleeping disorders, tardive dyskinesia, learning disorders, age-dependent memory disorders, eating disorders, and/or sexual dysfunctions, comprising administering to a host in need thereof an effective amount of a compound according to claim 1 and/or physiologically acceptable salts, ~~solvates~~ or stereoisomers thereof, including mixtures thereof in all ratios.

13. (Cancelled)

14. (Currently Amended) A kit consisting of separate packs of

- a) an effective amount of a compound according to Claim 1 and/or physiologically acceptable salts, ~~solvates~~ or stereoisomers thereof, including mixtures thereof in all ratios, and
- b) an effective amount of a further medicament active ingredient.

15. (New) A method of achieving an anxiolytic or anti-depressant effect comprising administering to a host in need thereof an effective amount of a compound according to claim 1 and/or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.